CClinicalTrials.gg
Sign In
RecruitingNCT07210671SUPERCATUpdated Apr 14, 2026

Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous

An observational study in Superficial Vein Thrombosis, Cancer and Venous Thrombosis, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.

Sponsored by Centre Hospitalier Universitaire, Amiens · Observational

From the registry’s dates

  • Started Nov 2025; still recruiting 10 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1,576
Ages
18 Years and older
Sex
All
01

Study summary

Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.

02

Conditions studied

  • Superficial Vein Thrombosis
  • Cancer
  • Venous Thrombosis

Keywords

  • Superficial vein thrombosis
  • cancer
  • venous thrombosis
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 1,576 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 576 studies on the registry; 178 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient with active cancer:

  • Cancer treatment within the last 6 months,
  • Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
  • The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
  • Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)

Inclusion criteria

  • Patient over 18
  • Patient affiliated to a social security scheme
  • Patient who understands French
  • Patient with superficial venous thrombosis of the lower and upper limbs confirmed by a Doppler ultrasound less than one month old.
  • Patient with active cancer:
  • Cancer treatment within the last 6 months,
  • Detectable tumor disease, cancer treatment within the last 6 months, ongoing hormone therapy for cancer, palliative cancer.
  • The patient has received potentially non-curative cancer treatment (notably palliative chemotherapy).
  • Progression shows that the cancer treatment was not curative (due to recurrence or progression under treatment) (particularly in the case of recurrence after surgery)

Exclusion criteria

Exclusion Criteria:

  • Patients under legal protection
  • Patients with concomitant pulmonary embolism
  • Patient with proximal or distal deep vein thrombosis
  • Patient treated with anticoagulant therapy for another indication
  • Patient with a contraindication to anticoagulation: Thrombocytopenia less than 30,000 elements/mm3, active bleeding or history of severe bleeding.
  • Patient opposed to participation in research
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1,576 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. risk (in %) of recurrence of VTE

    risk of recurrence of VTE at 3-month follow-up in patients with cancer-associated SVT.

    Time frame: at 3-month follow-up

Secondary outcomes

  1. association (%) between initial treatment and the risk of SVT recurrence

    Time frame: at 3 months

  2. association (%) between initial treatment and the risk of SVT recurrence

    Time frame: at 6 months

  3. association (%) between initial treatment and the risk of SVT recurrence

    Time frame: at 12 months

  4. Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

    Time frame: at 12 months

  5. Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

    Time frame: at 3 months

  6. Association (%) between initial treatment and the occurrence of DVT

    Time frame: at 3 months

  7. Association (%) between initial treatment and the occurrence of pulmonary embolism (PE)

    Time frame: at 6 months

  8. Association (%) between initial treatment and the occurrence of DVT

    Time frame: at 12 months

  9. Association (%) between initial treatment and the occurrence of DVT

    Time frame: at 6 months

  10. association (%) between initial treatment and bleeding events

    Time frame: at 6 months

  11. association (%) between initial treatment and bleeding events

    Time frame: at 3 months

  12. association (%) between initial treatment and bleeding events

    Time frame: at 12 months

  13. association(%) between initial treatment and all-cause death

    Time frame: at 3 months

  14. association(%) between initial treatment and all-cause death

    Time frame: at 6 months

  15. association(%) between initial treatment and all-cause death

    Time frame: at 12 months

  16. rates of recurrence of symptomatic vs. incidental VTE

    Time frame: at 3 months

  17. rates of recurrence of symptomatic vs. incidental VTE

    Time frame: at 6 months

  18. rates of recurrence of symptomatic vs. incidental VTE

    Time frame: at 12 months

  19. rate of confirmed cancer in patients with TVS suspected of having cancer.

    Time frame: at 12 months

07

Study locations

1 of 1 sites recruiting
  • CHU Amiens
    Amiens, 80480, France
    • SOUDET Simon, MD · Contact · soudet.simon@chu-amiens.fr · 03 22 88 72 89
    • Laurent Bertoletti, MD · Principal investigator
    • Lina Khider, MD · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07210671
Lead sponsor
Centre Hospitalier Universitaire, Amiens
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Nov 10, 2025
Primary completion
Nov 2027 (estimated)
Completion
Nov 2028 (estimated)
Last update
Apr 14, 2026

Study contacts

Simon SOUDET, Dr
Contact
soudet.simon@chu-amiens.fr
33+3 22 08 80 51

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

Centre Hospitalier Universitaire, Amiens

Start the discussion